Małgorzata Całbecka

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

Heinz Gisslinger, Christoph Klade, Pencho Georgiev et al. · The Lancet Haematology · 2020 · 347 citations

Pharmacy, Hematology, Pharmacotherapy +5

Comparison of Cladribine Plus Cyclophosphamide With Fludarabine Plus Cyclophosphamide As First-Line Therapy for Chronic Lymphocytic Leukemia: A Phase III Randomized Study by the Polish Adult Leukemia Group (PALG-CLL3 Study)

Tadeusz Robak, Krzysztof Jamroziak, Joanna Góra‐Tybor et al. · Journal of Clinical Oncology · 2010 · 99 citations · Full text

Medicine, Oncology, Pharmacology +16

A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in <i>FIP1L1‐PDGFRA‐</i>expressing patients

Grzegorz Helbig, Beata Stella‐Hołowiecka, Mirosław Majewski et al. · British Journal of Haematology · 2008 · 82 citations · Full text

Life Sciences, Hematology, Pharmacotherapy +12

Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial

Tadeusz Robak, Krzysztof Jamroziak, Joanna Góra‐Tybor et al. · Blood · 2007 · 75 citations · Full text

Medicine, Oncology, Pharmacology +11

Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine

Tadeusz Robak, Joanna Góra‐Tybor, Marek Kasznicki et al. · European Journal of Cancer · 2003 · 71 citations

Medicine, Hematology, Oncology +6